10. (Amended) The method according to claim 6 wherein the coprecipitant is selected from

inorganic salts,

sugars, polysaccharides, carbohydrates, polyols, and derivatives thereof with a molecular weight of less than 10,000 Da;

amino-acids;

acid-base buffers;

zwitterionic compounds;

organic salts;

compounds containing multiple basic groups;

compounds containing multiple acidic groups;

bile salts;

water soluble dyes;

polar or ionic polymers; and

polar or ionic dendrimers.

24. (Amended) Biological macromolecule coated micro-crystals comprising a coprecipitant core with a dehydrated biological macromolecule coated thereon wherein the coprecipitant is selected from inorganic salts,

sugars, polysaccharides, carbohydrates, polyols, and derivatives thereof with a molecular weight of less than 10,000 Da;

amino-acids;

acid-base buffers;

zwitterionic compounds;

organic salts;

compounds containing multiple basic groups;

compounds containing multiple acidic groups;

bile salts;

water soluble dyes;

polar or ionic polymers; and
polar or ionic dendrimers.

25. (Amended) A pharmaceutical formulation comprising biological macromolecule coated micro-crystals comprising a coprecipitant [cover] core with a dehydrated pharmaceutically active biological macromolecule coated thereon wherein the coprecipitant is selected from inorganic salts,
sugars, polysaccharides, carbohydrates, polyols, and derivatives thereof with a molecular weight of less than 10,000 Da;
amino-acids;
acid-base buffers;
zwitterionic compounds;
organic salts;
compounds containing multiple basic groups;
compounds containing multiple acidic groups;
bile salts;
water soluble dyes;
polar or ionic polymers; and
polar or ionic dendrimers; and a suitable carrier therefore.

Please add the following new claims:

33. Water soluble particles according to claim 5 wherein the coprecipitant is trehalose.

34. Water soluble particles according to claim 5 wherein the coprecipitant is an amino acid selected from the group consisting of glycine and arginine.

35. The method according to claim 10 wherein the coprecipitant is trehalose.

36. The biological macromolecule according to claim 24 wherein the coprecipitant is trehalose.

37. The biological macromolecule according to claim 24 wherein the coprecipitant is an amino acid selected from the group consisting of glycine and arginine.

38. The pharmaceutical formulation according to claim 25 wherein the coprecipitant is trehalose.

39. The pharmaceutical formulation according to claim 25 wherein the coprecipitant is an amino acid selected from the group consisting of glycine and arginine.

40. Water soluble particles according to claim 1 wherein said coprecipitant core is a non-polymeric core.

41. The method according to claim 6 wherein said coprecipitant core is a non-polymeric core.